Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy

Annals of Oncology

Volumn 23, Issue 5, 2012, Pages 1241-1249

  De Bono, J S ^a   Molife, L R ^a   Sonpavde, G ^b,c   Maroto, J P ^d   Calvo, E ^e   Cartwright, T H ^c,f   Loesch, D M ^g   Feit, K ^h   Das, A ⁱ   Zang, E A ^h   Wanders, J ^j   Agoulnik, S ^j   Petrylak, D P ^k  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b TEXAS ONCOLOGY   (United States)

^c Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f Ocala Oncology   (United States)

^g CARIS LIFE SCIENCES   (United States)

^h EISAI INC   (United States)

ⁱ GENENTECH INC   (United States)

^j EISAI CO LTD   (Japan)

^k Department of Medicine   (United States)

more..

Author keywords

Castrate resistance; Chemotherapy; Eribulin mesylate; Microtubule inhibitor; Prostate cancer; Prostate specific antigen

Indexed keywords

ERIBULIN; PROSTATE SPECIFIC ANTIGEN; TAXANE DERIVATIVE;

ADULT; ADVERSE OUTCOME; AGED; ALOPECIA; ANOREXIA; ANTIGEN FUNCTION; ARTICLE; ASTHENIA; BOLUS INJECTION; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL EVALUATION; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHARMACOGENOMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SCORING SYSTEM; THROMBOCYTOPENIA; TREATMENT DURATION; VISUAL ANALOG SCALE;

EID: 84859422181     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr380     Document Type: Article

References (28)

1. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
2. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
3. Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 2010; 10: 194-204.
4. Towle MJ, Salvato KA, Budrow J et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 2001; 61: 1013-1021.
5. Kuznetsov G, Towle MJ, Cheng H et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 2004; 64: 5760-5766.
6. Kuznetsov G, TenDyke K, Yu MJ, Littlefield BA. Antiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer cells in vitro. Proc Am Assoc Cancer Res 2007; 48: 275.
7. Goel S, Mita AC, Mita M et al. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid tumors. Clin Cancer Res 2009; 15: 4207-4212.
8. Tan AR, Rubin EH, Walton DC et al. Phase I study of eribulin mesylate (E7389) administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res 2009; 15: 4213-4218.
9. Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 3461-3467.
10. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
11. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
12. Petrylak DP, Ankerst DP, Jiang CS et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006; 98: 516-521.
13. Armstrong AJ, Garrett-Mayer E, Ou Yang YC et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007; 25: 3965-3970.
14. Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-1159.
15. Stein MN, Chen Y, Hudes GR et al. ECOG 5805: a phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC). J Clin Oncol 2010; 28 (Suppl 15): Abstr 4556.
16. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756-1764.
17. Vahdat LT, Pruitt B, Fabian CJ et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009; 27: 2954-2961.
18. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-1154.
19. Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 3089-3094.
20. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-422.
21. Attard G, Reid AH, A'Hern R et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27: 3742-3748.
22. Scher HI, Beer TM, Higano CS et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375: 1437-1446.
23. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
24. Hussain A, DiPaola RS, Baron AD et al. Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Ann Oncol 2009; 20: 492-497.
25. Galsky MD, Small EJ, Oh WK et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005; 23: 1439-1446.
26. Rosenberg JE, Weinberg VK, Kelly WK et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007; 110: 556-563.
27. Rosenberg JE, Ryan CJ, Weinberg VK et al. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. J Clin Oncol 2009; 27: 2772-2778.
28. Cortes J, O'Shaughnessy J, Loesch D et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011; 377 (9769): 914-923.